As of 26 April, the likelihood of approval (LoA) score for the RSV antibody respiratory syncytial virus (RSV) drug nirsevimab that is being developed by AstraZeneca and Sanofi climbed up 8 points. This change was prompted by an announcement on the same day stating that the Phase II/III MELODY trial investigating nirsevimab met its primary endpoint.

Data from MELODY will be part of nirsevimab’s regulatory submission slated for early 2022. Additionally, results from a Phase II/III MEDLEY trial comparing nirsevimab to Swedish Orphan Biovitrum’s Synagis (pavulizumab) in infants, and a Phase IIb study will also be part of the package. While detailed MELODY results are pending, nirsevimab reduced the incidence of medically attended lower respiratory tract infections (LRTI) due to RSV compared to placebo in healthy late preterm and term infants during their first RSV season, as per the 26 April press release. Nirsevimab has an extended half-life and is administered via a one-time intramuscular injection, while Synagis is administered monthly throughout the RSV season.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The LoA score which is calculated by GlobalData’s analysis that uses a combination of machine learning and a proprietary algorithm, was originally 36 points and is now at 44 points. While Synagis is only indicated for infants at high risk of RSV disease, nirsevimab is intended for use in all infants experiencing their first RSV season. As per an analyst’s best-case scenario, nirsevimab could rake in $1bn in peak sales. Global nirsevimab sales are estimated to reach $560m as per GlobalData Consensus forecast. AstraZeneca and Sanofi’s market caps are £101.27bn ($140bn) and €108.99bn ($131.14bn) respectively.

Manasi Vaidya is a Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.